Laurus Labs Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Laurus Labs Ltd filed with BSE on 30 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Laurus Labs reported Q1 FY27 revenue of INR2,026 crores, a 29% year-on-year increase, driven by growth in the CDMO segment and continued strength in the affordable medicines portfolio. EBITDA margin expanded to 31.8% and profit after tax was around INR368 crores, with management describing this as the highest quarterly revenue, EBITDA and profit for the company. Management also discussed capex plans, the CDMO and Bio segment updates, and progress on new modalities including ADCs, peptides and gene therapy.
Numbers mentioned
Revenue: INR2,026 crores (Q1 FY27)
p. 3
“The company's revenues were INR2,026 crores, showing a 29% growth.”
Satyanarayana Chava, page 3 of the filed PDF · View the filing
Gross margin: 62.7% (Q1 FY27)
p. 3
“Gross margins were also very healthy and maintained around 62.7% and EBITDA margins further expanded over previous quarter by 7 percentage points to 31.8%.”
Satyanarayana Chava, page 3 of the filed PDF · View the filing
EBITDA: INR644 crores (Q1 FY27)
p. 5
“EBITDA for the quarter 1 stands at INR644 crores with EBITDA margin of 31.8%, which is about 7% higher than before, which is”
V. V. Ravi Kumar, page 5 of the filed PDF · View the filing
Profit after tax: around INR368 crores (Q1 FY27)
p. 6
“Our profit after tax is around INR368 crores and ROCE is around 19% against 17.7% of the previous year.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
ROCE: 19% (Q1 FY27)
p. 6
“Our profit after tax is around INR368 crores and ROCE is around 19% against 17.7% of the previous year.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
Capex: INR394 crores (Q1 FY27)
p. 6
“On the capex front, we invested about INR394 crores for the quarter.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
Net debt: INR2,656 crores (Q1 FY27)
p. 6
“Our net debt stood at INR2,656 crores and debt-to-EBITDA is around 1.28 against 1.25 the last quarter on the back of strong internal cash flows.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
CDMO revenue: INR835 crores (Q1 FY27)
p. 4
“the division has continued to deliver strong operational execution in Q1, reporting a growth of 69% with the sales of INR835 crores on the small molecule side.”
Krishna Chava, page 4 of the filed PDF · View the filing
Laurus Bio revenue: INR35 crores (Q1 FY27)
p. 4
“Bio division reported a Q1 sales of about INR35 crores, which is about 21% growth year-on-year, which is broadly in line with our expectation.”
Krishna Chava, page 4 of the filed PDF · View the filing
Affordable Medicines revenue: INR1,156 crores (Q1 FY27)
p. 4
“Our Affordable Medicine division delivered a strong quarter 1 performance with revenue reaching to INR1,156 crores, which is an increase of 10% year-on-year.”
Soumya Chava, page 4 of the filed PDF · View the filing
R&D spend: 5.8% of revenue (Q1 FY27)
p. 5
“On R&D front, we spent 5.8% of our revenue on R&D, which is significantly higher, 70% more than the previous year.”
Satyanarayana Chava, page 5 of the filed PDF · View the filing
ARV API revenue: INR415 crores (Q1 FY27)
p. 7
“To answer your first question, for ARV APIs, we did about INR415 crores and ARV FDF is INR254 crores.”
Soumya Chava, page 7 of the filed PDF · View the filing
Cumulative product filings: 96 (as of Q1 FY27)
p. 5
“In developed market formulation dossiers, we filed 2 dossiers during Q1, taking our cumulative product filings to 96.”
Soumya Chava, page 5 of the filed PDF · View the filing
Forex gain: INR5 crores (Q1 FY27)
p. 11
“Forex gain on the balance sheet is about INR5 crores.”
V. V. Ravi Kumar, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
FY27-28 capex — more than INR3,000 crores · FY27 and FY28
stated conditionally by Satyanarayana Chava
p. 6
“Last quarter, we said INR3,000 crores for FY '27 and '28. We may do more than that, but we don't have a correct number to give you in this call.”
Satyanarayana Chava, page 6 of the filed PDF · View the filing
Gross margin — similar margins · coming quarters
stated firmly by Satyanarayana Chava
p. 10
“So we expect the similar margins we maintain for the coming quarters as well.”
Satyanarayana Chava, page 10 of the filed PDF · View the filing
Asset turnover ratio — a little over 1.0
stated as an aspiration by Satyanarayana Chava
p. 10
“We have clearly mentioned in our investor presentation, our first target is to reach asset turnover ratio a little over 1.0.”
Satyanarayana Chava, page 10 of the filed PDF · View the filing
CDMO share of revenue — at least 50% of revenue · FY30
stated firmly by Satyanarayana Chava
p. 11
“At this point, we are very comfortable to say that by FY '30, we will definitely reach our target of at least 50% of revenue come from CDMO segment.”
Satyanarayana Chava, page 11 of the filed PDF · View the filing
ROCE — 23%
stated conditionally by Satyanarayana Chava
p. 11
“And the ROCE because of heavy capex this year, maybe going to 23% will take some time.”
Satyanarayana Chava, page 11 of the filed PDF · View the filing
Laurus Bio Phase 1 capacity — a little over 400 kiloliters · towards the end of this year
stated firmly by Krishna Chava
p. 4
“we expect Phase 1 of this capacity, which is a little over 400 kiloliters is expected to be operational towards the end of this year.”
Krishna Chava, page 4 of the filed PDF · View the filing
Krka JV oncology facility — early next year
stated firmly by Satyanarayana Chava
p. 12
“The oncology facility will be ready early next year and then solid oral facility will be second half of 2027 calendar year.”
Satyanarayana Chava, page 12 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the increase reflects capacity requirements to meet customer demand.
Answered by Satyanarayana Chava
Asked by Vandit Dharamshi: Why has FY27 capex guidance nearly doubled from INR1,000 crores to INR1,500-2,000 crores?
p. 6
“The increase in numbers for the capex spend broadly based on our requirement for capacity to meet our customer demands.”
Satyanarayana Chava, page 6 of the filed PDF · View the filing
About 55% of CDMO revenue came from commercial supplies.
Answered by Satyanarayana Chava
Asked by Tushar Manudhane: What proportion of small molecule CDMO revenue is from commercial versus non-commercial supplies?
p. 7
“So in the small molecule CDMO business, about 55% of revenue came from commercial supplies.”
Satyanarayana Chava, page 7 of the filed PDF · View the filing
Management said non-ARV is currently 2/3 and expects that share to remain the highest or increase further.
Answered by Satyanarayana Chava
Asked by Krish Mehta: Has the ARV to non-ARV revenue mix stabilized at 1/3 to 2/3?
p. 7
“See, currently, 2/3rd is non-ARV and 1/3rd is ARV. We expect this will be the highest and I expect it will go down further, but I don't think it will go up beyond this number.”
Satyanarayana Chava, page 7 of the filed PDF · View the filing
Management said gross margin improved quarter-on-quarter from 61% to 63%, with modest year-on-year improvement, and some margin pressure from global conflicts.
Answered by Satyanarayana Chava
Asked by Dhanshyam Meena: Why haven't gross margins improved as much as operating profits despite CDMO ramp-up?
p. 10
“our gross margin also improved from 61% to 63%. That's from quarter-on-quarter. But when compared to year-on-year, it is almost a little over 3% increase was there.”
Satyanarayana Chava, page 10 of the filed PDF · View the filing
Management said it could not discuss project-specific details but expects peptides to be meaningful for the company.
Answered by Krishna Chava
Asked by Rehan: Has the company qualified commercial-scale synthesizers for GLP-1 peptides like semaglutide?
p. 11
“Unfortunately, we are not able to discuss any project-specific details, but we expect peptides to be a meaningful area for Laurus as a company.”
Krishna Chava, page 11 of the filed PDF · View the filing
Management said INR400 crores invested so far, another INR400 crores needed, with the oncology facility ready early next year and solid oral facility in H2 2027.
Answered by Satyanarayana Chava
Asked by Manoj Bahety: How much more capex is needed for the Krka JV and when will revenues start?
p. 12
“Currently, we have invested so far INR400 crores. And then that facility needs another INR400 crores. And part of that investment will come from loan from our partner.”
Satyanarayana Chava, page 12 of the filed PDF · View the filing
Management declined to give a specific number, saying value per program matters more than the count of programs.
Answered by Satyanarayana Chava
Asked by Mitul Mehta: Can management give a total addressable market size for the CDMO pipeline?
p. 13
“I think we don't want to confuse all our investors by giving a certain number of projects we're handling or certain percentage of and all.”
Satyanarayana Chava, page 13 of the filed PDF · View the filing
Management said last financial year the commercial contribution was 50%, and expects it to grow.
Answered by Satyanarayana Chava
Asked by Dhawal Khut: What percentage of custom synthesis sales in FY26 came from commercial supplies compared to 55% this quarter?
p. 15
“It's 50% came from commercial supplies last financial year.”
Satyanarayana Chava, page 15 of the filed PDF · View the filing
Management confirmed yes, some molecules generate that level of revenue.
Answered by Krishna Chava
Asked by Dhanshyam Meena: Do any molecules in the CDMO business generate around INR200 crores or more?
p. 18
“Yes. The answer is yes. Yes, we do have.”
Krishna Chava, page 18 of the filed PDF · View the filing
Risks flagged
Margin pressure from global conflicts affecting raw material costs
p. 10
“We have seen some pressure on margins because of the global conflicts, but that margin pressure is not that significant to take a shelter that because of that margins have gone down.”
Satyanarayana Chava, page 10 of the filed PDF · View the filing
Uncertainty over which fermentation-based programs will succeed
p. 9
“Our next 12 to 18 months will be very crucial which molecule, which program in our precision fermentation will take off, which will not take off.”
Satyanarayana Chava, page 9 of the filed PDF · View the filing
No returns expected from advanced biologics investments in the near term
p. 9
“See, one segment, our investments are not going to give returns is our advanced biologics, our investments into gene therapy, ADCs and all.”
Satyanarayana Chava, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.